{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T10:26:22Z","timestamp":1783506382125,"version":"3.55.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The French Journal of Urology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.fjurol.2025.102934","type":"journal-article","created":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T23:41:09Z","timestamp":1753314069000},"page":"102934","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Relugolix in prostate cancer therapy: Clinical evidence and practical considerations"],"prefix":"10.1016","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1158-0082","authenticated-orcid":false,"given":"Arthur","family":"Peyrottes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Baboudjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Barret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Brureau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Dariane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Olivier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6004-2152","authenticated-orcid":false,"given":"Guillaume","family":"Ploussard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Sargos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephane","family":"Supiot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Mathieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.fjurol.2025.102934_bib0260","series-title":"Prostate cancer burden in EU-27","year":"2021"},{"key":"10.1016\/j.fjurol.2025.102934_bib0265","doi-asserted-by":"crossref","first-page":"102717","DOI":"10.1016\/j.fjurol.2024.102717","article-title":"French AFU Cancer Committee Guidelines - update 2024\u20132026: prostate cancer - diagnosis and management of localised disease","volume":"34","author":"Ploussard","year":"2024","journal-title":"Fr J Urol"},{"key":"10.1016\/j.fjurol.2025.102934_bib0270","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.annonc.2020.06.011","article-title":"Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Parker","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.fjurol.2025.102934_bib0275","series-title":"Guidelines on Prostate Cancer","year":"2025"},{"key":"10.1016\/j.fjurol.2025.102934_bib0280","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.annonc.2023.02.015","article-title":"Updated treatment recommendations for prostate cancer from the ESMO Clinical Practice Guideline considering treatment intensification and use of novel systemic agents","volume":"34","author":"Fizazi","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.fjurol.2025.102934_bib0285","first-page":"87","article-title":"Evolution of androgen deprivation therapy (ADT) and its new emerging modalities in prostate cancer: an update for practicing urologists, clinicians and medical providers","volume":"14","author":"Choi","year":"2022","journal-title":"Res Rep Urol"},{"key":"10.1016\/j.fjurol.2025.102934_bib0290","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.eururo.2014.07.010","article-title":"Adverse effects of androgen deprivation therapy and strategies to mitigate them","volume":"67","author":"Nguyen","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2025.102934_bib0295","series-title":"Firmagon. Summary of Product Characteristics","year":"2013"},{"key":"10.1016\/j.fjurol.2025.102934_bib0300","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1111\/j.1464-410X.2008.08183.x","article-title":"The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer","volume":"102","author":"Klotz","year":"2008","journal-title":"BJU Int"},{"key":"10.1016\/j.fjurol.2025.102934_bib0305","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s11523-022-00944-4","article-title":"Relugolix: a review in advanced prostate cancer","volume":"18","author":"Shirley","year":"2023","journal-title":"Target Oncol"},{"key":"10.1016\/j.fjurol.2025.102934_bib0310","doi-asserted-by":"crossref","first-page":"5891","DOI":"10.1002\/cam4.2442","article-title":"Phase I trial of TAK-385 in hormone treatment-naive Japanese patients with nonmetastatic prostate cancer","volume":"8","author":"Suzuki","year":"2019","journal-title":"Cancer Med"},{"key":"10.1016\/j.fjurol.2025.102934_bib0315","doi-asserted-by":"crossref","first-page":"4579","DOI":"10.1210\/jc.2015-2770","article-title":"Medical castration using the investigational oral GnRH antagonist TAK-385 (relugolix): phase 1 study in healthy males","volume":"100","author":"MacLean","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.fjurol.2025.102934_bib0320","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.eururo.2020.03.001","volume":"78","author":"Dearnaley","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2025.102934_bib0325","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1200\/jco.2016.34.2_suppl.200","article-title":"Second interim analysis (IA2) results from a phase II trial of TAK-385, an oral GnRH antagonist, in prostate cancer patients (pts)","volume":"34","author":"Saad","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.fjurol.2025.102934_bib0330","first-page":"156","article-title":"Safety and tolerability of relugolix in combination with abiraterone or apalutamide for treatment of patients with advanced prostate cancer: data from a 52-Week clinical trial","volume":"43","author":"De La Cerda","year":"2025","journal-title":"Target Oncol"},{"key":"10.1016\/j.fjurol.2025.102934_bib0335","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s11523-022-00932-8","article-title":"Coadministration of apalutamide and relugolix in patients with localized prostate cancer at high risk for metastases","volume":"18","author":"Brown","year":"2023","journal-title":"Target Oncol"},{"key":"10.1016\/j.fjurol.2025.102934_bib0340","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa2004325","article-title":"Oral relugolix for androgen-deprivation therapy in advanced prostate cancer","volume":"382","author":"Shore","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.fjurol.2025.102934_bib0345","series-title":"Orgovxy. Summary of Product Characteristics","year":"2024"},{"key":"10.1016\/j.fjurol.2025.102934_bib0350","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1093\/oncolo\/oyad036","article-title":"A practical guide to relugolix: early experience with oral androgen deprivation therapy","volume":"28","author":"Kasparian","year":"2023","journal-title":"Oncologist"},{"key":"10.1016\/j.fjurol.2025.102934_bib0355","doi-asserted-by":"crossref","DOI":"10.1177\/17562872241293779","article-title":"Testosterone suppression and recovery in patients with advanced prostate cancer treated with intermittent androgen deprivation therapy with relugolix","volume":"16","author":"Campbell","year":"2024","journal-title":"Ther Adv Urol"},{"key":"10.1016\/j.fjurol.2025.102934_bib0360","doi-asserted-by":"crossref","first-page":"65.e1","DOI":"10.1016\/j.urolonc.2024.08.005","article-title":"Testosterone recovery after androgen deprivation therapy","volume":"43","author":"Ho","year":"2025","journal-title":"Urol Oncol"},{"key":"10.1016\/j.fjurol.2025.102934_bib0365","doi-asserted-by":"crossref","first-page":"1289249","DOI":"10.3389\/fonc.2023.1289249","article-title":"Early biochemical outcomes following neoadjuvant\/adjuvant relugolix with stereotactic body radiation therapy for intermediate to high risk prostate cancer","volume":"13","author":"Gallagher","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.fjurol.2025.102934_bib0370","doi-asserted-by":"crossref","first-page":"1412786","DOI":"10.3389\/fonc.2024.1412786","article-title":"The impact of neoadjuvant relugolix on multi-dimensional patient-reported fatigue","volume":"14","author":"Hsueh","year":"2024","journal-title":"Front Oncol"},{"key":"10.1016\/j.fjurol.2025.102934_bib0375","doi-asserted-by":"crossref","first-page":"1377103","DOI":"10.3389\/fonc.2024.1377103","article-title":"Impact of neoadjuvant relugolix on patient-reported sexual function and bother","volume":"14","author":"Hsueh","year":"2024","journal-title":"Front Oncol"},{"key":"10.1016\/j.fjurol.2025.102934_bib0380","doi-asserted-by":"crossref","first-page":"4854","DOI":"10.3390\/cancers15194854","article-title":"Relugolix vs. leuprolide effects on castration resistance-free survival from the phase 3 HERO study in men with advanced prostate cancer","volume":"15","author":"Saad","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.fjurol.2025.102934_bib0385","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1001\/jamaoncol.2023.7279","article-title":"Efficacy and safety of radiotherapy plus relugolix in men with localized or advanced prostate cancer","volume":"10","author":"Spratt","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.fjurol.2025.102934_bib0395","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.clgc.2023.03.009","article-title":"Impact of concomitant prostate cancer medications on efficacy and safety of relugolix versus leuprolide in men with advanced prostate cancer","volume":"21","author":"George","year":"2023","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.fjurol.2025.102934_bib0430","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.euo.2023.11.024","article-title":"Testosterone recovery for relugolix versus leuprolide in men with advanced prostate cancer: results from the phase 3 HERO study","volume":"7","author":"Tutrone","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.fjurol.2025.102934_bib0435","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.eururo.2023.09.007","article-title":"Impact of relugolix versus leuprolide on the quality of life of men with advanced prostate cancer: results from the phase 3 HERO study","volume":"84","author":"Tombal","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2025.102934_bib0390","doi-asserted-by":"crossref","first-page":"100575","DOI":"10.1016\/j.esmoop.2022.100575","article-title":"Addition of androgen receptor-targeted agents to androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis","volume":"7","author":"Maiorano","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.fjurol.2025.102934_bib0400","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1097\/JU.0000000000000384","article-title":"Cardiovascular morbidity in a randomized trial comparing GnRH agonist and GnRH antagonist among patients with advanced prostate cancer and preexisting cardiovascular disease","volume":"202","author":"Margel","year":"2019","journal-title":"J Urol"},{"key":"10.1016\/j.fjurol.2025.102934_bib0405","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.eururo.2013.10.032","article-title":"Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist","volume":"65","author":"Albertsen","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2025.102934_bib0410","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1097\/JU.0000000000001879","article-title":"Cardiovascular proteomics: a post hoc analysis from a phase ii randomized clinical trial comparing GnRH antagonist vs GnRH agonist among men with advanced prostate cancer","volume":"206","author":"Lifshitz","year":"2021","journal-title":"J Urol"},{"key":"10.1016\/j.fjurol.2025.102934_bib0415","doi-asserted-by":"crossref","first-page":"4919","DOI":"10.1007\/s12325-023-02634-7","article-title":"Impact of concomitant cardiovascular therapies on efficacy and safety of relugolix vs leuprolide: subgroup analysis from HERO study in advanced prostate cancer","volume":"40","author":"Shore","year":"2023","journal-title":"Adv Ther"},{"key":"10.1016\/j.fjurol.2025.102934_bib0420","doi-asserted-by":"crossref","first-page":"110256","DOI":"10.1016\/j.radonc.2024.110256","article-title":"Testosterone recovery after androgen deprivation therapy in localised prostate cancer: long-term data from two randomised trials","volume":"195","author":"Nabid","year":"2024","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.fjurol.2025.102934_bib0425","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.eururo.2024.09.009","article-title":"Testosterone recovery following androgen suppression and prostate radiotherapy (TRANSPORT): a pooled analysis of five randomized trials from the meta-analysis of randomized trials in cancer of the prostate (MARCAP) consortium","volume":"87","author":"Ong","year":"2025","journal-title":"Eur Urol"},{"issue":"Suppl. 424","key":"10.1016\/j.fjurol.2025.102934_bib0440","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1200\/JCO.2024.42.4_suppl.301","article-title":"Relugolix versus leuprolide in combination with radiotherapy for localized prostate cancer (REVELUTION trial): an initial analysis of patient treatment preferences and quality of life","volume":"42","author":"Patel","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.fjurol.2025.102934_bib0445","doi-asserted-by":"crossref","first-page":"727","DOI":"10.2217\/fon-2023-0748","article-title":"Evaluating relugolix for the treatment of prostate cancer in real-world settings of care: the OPTYX study protocol","volume":"20","author":"Spratt","year":"2024","journal-title":"Future Oncol"},{"key":"10.1016\/j.fjurol.2025.102934_bib0450","series-title":"RENAISSANCE - A multi-centre, non-interventional study of RElugolix as aNdrogen-deprivAtion therapy In patientS with advanced hormone-Sensitive prostate cANCEr: clinical study protocol.","year":"2024"},{"key":"10.1016\/j.fjurol.2025.102934_bib0510","unstructured":"clinicaltrials.gov. RElugolix VErsus LeUprolide Cardiac Trial (REVELUTION), https:\/\/clinicaltrials.gov\/study\/NCT05320406; 2024. [accessed February 2025]."},{"issue":"Suppl. 16","key":"10.1016\/j.fjurol.2025.102934_bib0460","doi-asserted-by":"crossref","first-page":"e17072","DOI":"10.1200\/JCO.2024.42.16_suppl.e17072","article-title":"Interim analysis of clinical data and reasons for initiating relugolix on a cohort of US patients: the OPTYX study","volume":"42","author":"Spratt","year":"2024","journal-title":"J Clin Oncol"},{"issue":"Suppl. 6","key":"10.1016\/j.fjurol.2025.102934_bib0455","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1200\/JCO.2023.41.6_suppl.74","article-title":"Real-world combination therapy patterns in patients receiving leuprolide or relugolix for androgen deprivation therapy in 2021 (the REAL-ADT COMBO Study): analysis from a US EMR database","volume":"41","author":"McKay","year":"2023","journal-title":"J Clin Oncol"},{"issue":"Suppl. 4","key":"10.1016\/j.fjurol.2025.102934_bib0465","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1200\/JCO.2024.42.4_suppl.85","article-title":"Real-world experience on tolerability and safety of relugolix combined with androgen signaling inhibitors in patients with advanced prostate cancer","volume":"42","author":"Guan","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.fjurol.2025.102934_bib0470","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1097\/JU.0000000000003081","article-title":"Adherence with oral anticancer therapies: clinical trial vs real-world experiences with a focus on prostate cancer","volume":"209","author":"Higano","year":"2023","journal-title":"J Urol"},{"key":"10.1016\/j.fjurol.2025.102934_bib0475","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1097\/UPJ.0000000000000445","article-title":"Adherence to hormonal therapies in prostate cancer","volume":"10","author":"Hafron","year":"2023","journal-title":"Urol Pract"},{"issue":"Suppl. 4","key":"10.1016\/j.fjurol.2025.102934_bib0480","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1200\/JCO.2024.42.4_suppl.319","article-title":"Utilization of patient-reported outcomes to assess adherence to relugolix when combined with radiation therapy","volume":"42","author":"Gaudian","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.fjurol.2025.102934_bib0485","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/cpt.2743","article-title":"Population PK and semimechanistic PK\/PD modeling and simulation of relugolix effects on testosterone suppression in men with prostate cancer","volume":"113","author":"Lee","year":"2023","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.fjurol.2025.102934_bib0490","doi-asserted-by":"crossref","first-page":"e389516","DOI":"10.1200\/EDBK_389516","article-title":"Shared decision making in the care of patients with cancer","volume":"43","author":"Shickh","year":"2023","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.fjurol.2025.102934_bib0495","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s40271-023-00638-7","article-title":"Discrete-choice experiment to understand the preferences of patients with hormone-sensitive prostate cancer in the USA, Canada, and the UK","volume":"16","author":"Gonzalez","year":"2023","journal-title":"Patient"},{"key":"10.1016\/j.fjurol.2025.102934_bib0500","doi-asserted-by":"crossref","first-page":"3934","DOI":"10.1007\/s12325-024-02955-1","article-title":"Patient preferences for attributes of androgen deprivation therapies in prostate cancer: a discrete choice experiment with latent class analysis","volume":"41","author":"Hauber","year":"2024","journal-title":"Adv Ther"},{"key":"10.1016\/j.fjurol.2025.102934_bib0505","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1007\/s11255-024-04028-2","article-title":"Patient preference on once-daily oral versus injectable androgen deprivation therapy for Asian patients with advanced prostate cancer","volume":"56","author":"Wong","year":"2024","journal-title":"Int Urol Nephrol"}],"container-title":["The French Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950393025000816?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950393025000816?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T03:10:28Z","timestamp":1762657828000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950393025000816"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":51,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S2950393025000816"],"URL":"https:\/\/doi.org\/10.1016\/j.fjurol.2025.102934","relation":{},"ISSN":["2950-3930"],"issn-type":[{"value":"2950-3930","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Relugolix in prostate cancer therapy: Clinical evidence and practical considerations","name":"articletitle","label":"Article Title"},{"value":"The French Journal of Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.fjurol.2025.102934","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"102934"}}